Heron Therapeutics stock forecast
Heron Therapeutics (AXD2) Stock Forecast & Price Target
AXD2 Analyst Ratings
AXD2 Stock 12 Month Forecast
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Brandon Folkes | H.C. Wainwright | ― | hold | ― | Reiterated | 11/13/26 | ||
| Serge Belanger | Needham | ― | hold | ― | Reiterated | 08/10/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Brandon FolkesH.C. Wainwright | HoldReiterated | 11/13/26 | ― | ||
| Serge BelangerNeedham | HoldReiterated | 08/10/26 | ― |
Best Analysts Covering Heron Therapeutics
Copying PerPlexity Biotechnology's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.45% per trade.
Copying PerPlexity Biotechnology's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.45% per trade.
Copying PerPlexity Biotechnology's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +0.45% per trade.
AXD2 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 4 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 5 | 6 | 3 | 3 | 1 |
In the current month, AXD2 has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AXD2 average Analyst price target in the past 3 months is ―.
AXD2 Financial Forecast
AXD2 Earnings Forecast
Next quarter’s earnings estimate for AXD2 is -CHF 0.03 with a range of -CHF 0.03 to -CHF 0.02. The previous quarter’s EPS was -CHF 0.03. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
AXD2 Sales Forecast
Next quarter’s sales forecast for AXD2 is CHF 28.53M with a range of CHF 26.43M to CHF 30.63M. The previous quarter’s sales results were CHF 29.58M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.

